A case-control study of serious autoimmune adverse events following hepatitis B immunization

Autoimmunity ◽  
2005 ◽  
Vol 38 (4) ◽  
pp. 295-301 ◽  
Author(s):  
David A. Geier ◽  
David A. Geier ◽  
Mark R. Geier ◽  
David A. Geier ◽  
Mark R. Geier
2008 ◽  
Vol 89 (11) ◽  
pp. 2882-2890 ◽  
Author(s):  
Zhong-Liao Fang ◽  
Caroline A. Sabin ◽  
Bai-Qing Dong ◽  
Shao-Chao Wei ◽  
Qin-Yan Chen ◽  
...  

A matched nested case–control study of 33 paired cases and controls was conducted, based on a study cohort in Long An county, Guangxi, China, to determine whether infection with hepatitis B virus (HBV) with pre-S deletions is independently associated with the development of hepatocellular carcinoma (HCC), without the confounding effects of basal core promoter (BCP) double mutations. The prevalence of pre-S deletions was significantly higher in HCC (45.5 %, 15 of 33) than the controls (18.2 %, 6 of 33) (P<0.01), under the control of the influence of BCP double mutations. Most of the pre-S deletions occurred in, or involved, the 5′ half of the pre-S2 region and the difference between HCC (93.3 %, 14 of 15) and controls (66.7 %, four of six) was significant for this region (P=0.015). There was no significant difference in pre-S deletions between the BCP mutant group and BCP wild-type group (P>0.05), nor was the prevalence of pre-S deletions significantly different between genotypes B and C (P>0.1). These results suggest that pre-S deletions constitute an independent risk factor for HCC and their emergence and effect are independent of BCP mutations. The 5′ terminus of pre-S2 is the favoured site for the deletion mutations, especially in HCC cases. Further prospective studies are required to confirm the role of these mutations in the development of HCC.


Vaccine ◽  
2021 ◽  
Vol 39 (43) ◽  
pp. 6364-6369
Author(s):  
Anna Melgaard ◽  
Lene Wulff Krogsgaard ◽  
Tina Hovgaard Lützen ◽  
Oleguer Plana-Ripoll ◽  
Bodil Hammer Bech ◽  
...  

2013 ◽  
Vol 31 (4) ◽  
pp. 278-280 ◽  
Author(s):  
Itai Shavit ◽  
Liat Feraru ◽  
Dan Miron ◽  
Giora Weiser

ObjectivesBased on the 2010 Israeli Medical Association recommendations, young children with suspected urinary tract infection (UTI) are mildly sedated with oral or intranasal midazolam to reduce the distress associated with urethral catheterisation (UC). The primary objective of this study was to examine the rate of urine culture contamination (UCC) in infants who underwent UC with and without sedation. Other objectives were to evaluate serious adverse events and emergency department (ED) length of stay.MethodsA retrospective case-control study was conducted in a paediatric ED.ResultsTwo cohorts of patients who underwent UC were compared, 164 female infants who were sedated with midazolam (case subjects) and 173 who were not (controls). Cases and controls had a mean temperature of 38.3°C and 38.2°C, respectively. One hundred and forty-one patients were treated with oral midazolam and 23 received the drug intranasally. Cases and controls had a UCC rate of 20/164 (12%) and 45/173 (26%), respectively. Compared with controls, cases had lower odds of UCC (OR=0.39, 95% CI 0.21 to 0.73).Serious adverse events related to midazolam were not recorded. Case subjects and controls had a mean ED length of stay of 2.96 h and 2.50 h, respectively. The difference between the groups was statistically significant (p<0.014, 95% CI 0.10 to 0.90 for difference between means).ConclusionsIn this cohort of febrile infants, sedation with oral or intranasal midazolam reduced the risk of culture contamination during UC without causing serious adverse events. However, patients who were treated with sedation had longer length of stay in the ED.


2017 ◽  
Vol 25 (1) ◽  
pp. 97-104 ◽  
Author(s):  
R. W. H. Hui ◽  
W.-K. Seto ◽  
K.-S. Cheung ◽  
L.-Y. Mak ◽  
K. S. H. Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document